Jiangsu Hengrui Pharmaceuticals (01276): HRS-1780 tablets receive approval notice for drug clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. has received the approval and issuance of the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for HRS-1780 tablets, and will soon begin clinical trials. HRS-1780 tablets are a mineralocorticoid receptor antagonist, intended for the treatment of heart failure in adults with left ventricular ejection fraction 40%. Currently, the main drugs used in the treatment of heart failure include angiotensin receptor/neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors. As of now, the total research and development investment for the HRS-1780 tablet project is approximately 67.8 million yuan.